CurifyLabs has introduced its acquisition of serious mental property (IP) from Mehta Heino Industries Oy, a specialist in 3D printing {hardware} growth. CurifyLabs says the acquisition marks a pivotal second in its functionality to supply “unparalleled” 3D printing options for producing personalised medicines within the pharma business.
“The acquisition of Mehta Heino’s IP and different property is a game-changer for us. Their modern strategy to 3D printing expertise completely aligns with our imaginative and prescient enabling wider adoption of personalised therapies. This acquisition just isn’t merely about rising our portfolio; its about leadding the business into a brand new period,” mentioned Charlotta Topelius, Co-Founder and CEO of CurifyLabs.
Along with the IP acquisition, Petri Heino, CTO of Mehta Heino joins CurifyLabs as Lead {Hardware} Engineer, which the corporate says additional strengthens its place in redefining the panorama of options in personalised drugs manufacture.
Heino mentioned: “CurifyLabs presents a unprecedented alternative to push the boundaries of what’s attainable in 3D printing and superior robotics in healthcare. Me and my Co-Founder Santosh Mehta spent eight years creating our expertise and we’re thrilled to see our IP contribute to groundbreaking developments for the good thing about susceptible affected person populations that want personalised therapies.”
Learn extra: CurifyLabs launches 3D printing answer for personalised drugs
CurifyLabs’ Pharma Package answer, which mixes printable pharma inks with 3D printing expertise and high quality management, offers an automatic answer for producing personalised drugs in hospitals and compounding pharmacies in keeping with the corporate. The answer is claimed to remove the guide course of and makes compounding extra accessible, cost-effective, protected, and scalable.
Niklas Sandler, Co-Founder and CTO at CurifyLabs mentioned: “For pharmacies, pace, seamless workflows, and regulatory compliance are important. We allow this with our distinctive personalised drugs manufacturing answer. With Mehta Heino’s IP, we’re taking our dedication to efficient options to the subsequent stage. Our mixed experience will lead to extra environment friendly manufacturing options, facilitating the broader adoption of personalised drugs and enhanced take care of sufferers with particular person wants.”
CurifyLabs says that the demand for personalised drugs is rising, and uniformed drug therapies usually fall wanting addressing the distinctive wants of sufferers. CurifyLabs says {that a} report by the European Fee detailed that over 50% of medicines are usually not registered to be used in youngsters. The corporate goals to focus product growth particularly on paediatric populations in an try to handle this.
Tophelius added: “We should pay particular consideration to pediatric populations the place personalised medicines are essential. The IP acquisition and including Petri to our crew improve our means to just do that.”
